Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc. reported a strong +25% growth in revenue for Q4, driven by a +17% increase in volume and a +5% rise in average selling prices, alongside record revenue from patient and digital solutions. The company saw positive momentum in earlier quarters as well, with a +21% revenue increase in Q3 supported by similar trends in volume and average selling prices, culminating in the highest cash collections in its history in October. Furthermore, CareDx has raised its revenue estimates for 2026 and 2027, anticipating continued strong performance bolstered by an expanded sales force and high return on investment from ongoing business investments.

Bears say

CareDx Inc. faces a negative outlook primarily due to anticipated revenue impacts from the proposed LCD regulation, with a projected $7.5 million decrease in revenues reflected in its 2026 guidance, illustrating challenges in maintaining growth amid changing regulatory environments. Furthermore, while the company reported a year-over-year increase in testing volumes, the performance fell short of expectations, indicating potential weakness in demand and commercialization of additional diagnostic solutions critical to the company’s growth strategy. Lastly, CareDx's shares are trading at a significantly lower multiple compared to historical averages and peers in the diagnostics industry, with a low EBITDA margin run-rate of 16%, highlighting concerns regarding profitability and overall market confidence in the stock.

CareDx (CDNA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 6 analysts, CareDx (CDNA) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.